CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (52,788)	$ (118,607)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14,812	5,967
Inventory impairment charges	1,563	173
Share-based compensation	41,885	22,905
Amortization of discount and cost of issuance of debt	417	198
Bad debts	24	(158)
Gain from change in fair value remeasurement of SAFEs	0	(21,600)
(Gain) loss from change in fair value of warrants	(55,069)	26,060
Loss from change in fair value of earn-out liabilities	0	38,758
(Gain) loss from change in fair value of contingent considerations	(9,468)	131
Gain from change in fair value of currency forward contract	(208)	0
Gain from extinguishment of debt	0	(304)
Deferred City Semi compensation	222	500
Deferred tax liabilities	(2,002)	(516)
Amortization of right-of-use assets	1,949	0
Unrealized foreign currency transaction (gain) loss	8	(86)
Changes in operating assets and liabilities:
Accounts receivable	(12,161)	(4,477)
Inventory	(4,299)	(3,171)
Accounts payable	7,419	(2,476)
Accrued expenses and other current liabilities	1,665	1,432
Accrued payroll liabilities	528	3,950
Deferred revenue	(301)	(837)
Prepaid and other current assets	(8,175)	(3,706)
Operating lease liabilities	(1,488)	0
Other long-term liabilities	(1,278)	45
Net cash used in operating activities	(76,745)	(55,819)
Cash flows from investing activities:
Purchases of property and equipment	(7,568)	(2,682)
Purchases of intangible assets	0	(1,388)
Business combinations, net of cash	(8,705)	(80,256)
Net cash used in investing activities	(16,273)	(84,326)
Cash flows from financing activities:
Proceeds from issuance of SAFEs	0	5,000
Proceeds from issuance of common stock/At-the-market offering	17,203	0
Offering costs for the issuance of common stock/At-the-market offering	(379)	0
Proceeds from Wuxi Capital Raise	41,861	0
Issuance Costs related to Wuxi Capital Raise	(39)	0
Proceeds from issuance of debt obligations	161,507	775
Issuance and discount costs related to 2027 Notes	(5,374)	0
Proceeds from reverse recapitalization	0	377,663
Issuance costs related to reverse recapitalization	0	(19,902)
Payments on debt obligations	(2,158)	(17,543)
Payments on financed software	(4,161)	(2,270)
Redemption of Class H units	0	(900)
Deferred payments on business combination	(7,500)	0
Payments of City Semi deferred compensation	(1,000)	(399)
Taxes paid related to net share settlement of vested equity awards	0	(1,844)
Repurchase of common stock	(7,404)	0
Proceeds from exercise of stock options	103	66
Net cash provided by financing activities	192,659	340,646
Effect of exchange rate changes on cash, and cash equivalents	2,774	265
Net increase in cash and cash equivalents	102,415	200,766
Cash, cash equivalents, and restricted cash at beginning of period	219,464	18,698
Cash, cash equivalents, and restricted cash at end of period	321,879	219,464
Supplemental disclosure of cash flow information:
Cash paid for interest	376	1,234
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment, accrued but not paid	1,464	240
Conversion of historical members' equity	0	41,278
Class G warrants cashless exchange	0	407
Conversion of SAFEs	0	86,100
Conversion of Embry Notes	0	4,119
Recognition of earn-out considerations	0	119,759
Recognition of warrant liabilities	0	74,408
Accrual for purchases of intangible assets	0	17,820
Fair value of common stock issued for business combination	0	82,441
Contingent consideration for business combination	7,836	4,000
Accrual for purchase consideration for business combination	$ 9,674	$ 7,500